Premium
Tiratricol Neutralizes Bacterial Endotoxins and Reduces Lipopolysaccharide‐Induced TNF‐α Production in the Cell
Author(s) -
Cascales Laura,
MasMoruno Carlos,
Tamborero Silvia,
Aceña José Luis,
SanzCervera Juan F.,
Fustero Santos,
Cruz Luis J.,
Mora Puig,
Albericio Fernando,
PérezPayá Enrique
Publication year - 2008
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/j.1747-0285.2008.00703.x
Subject(s) - lipopolysaccharide , chemistry , drug discovery , tumor necrosis factor alpha , drug , bacterial cell structure , microbiology and biotechnology , bacteria , combinatorial chemistry , computational biology , pharmacology , biochemistry , biology , immunology , genetics
The screening of a commercially available library of compounds has proved a successful strategy for the identification of a lead compound in a drug discovery programme. Here, we analysed 880 off‐patent drugs, which initially comprised the Prestwick Chemical library, as sources of bacterial endotoxin neutralizers. We identified 3,3′,5‐triiodo‐thyroacetic acid (tiratricol) as a non‐antibacterial compound that neutralizes the toxic lipopolysaccharide.